Table 2. Studies included in the review.
| Trial ID | Summary details | Arm 1: taxane containing a | Arm 2: control | Majority first line for MBC | Majority anthracycline naïve | Accrual |
|---|---|---|---|---|---|---|
| Regimen A plus taxane vs Regimen A | ||||||
| ECOG E1193 (A) (Sledge et al, 2003) | Open: 1993–1995 | AT (paclitaxel+doxorubicin+G-CSF) | Doxorubicin | Y | Y | 739 |
| EU-93011 (Heidemann, 2005) | Open: 1994–(ongoing) | Docetaxel+mitoxantrone | mitoxantrone | Y | Both | 300 |
| SAKK (Goldhirsch, 2005) | Open: unk (ongoing) | Paclitaxel+trastuzumab | trastuzumab | Y | Both | 170–250 |
| Regimen A plus taxane vs Regimen B | ||||||
| 306 Study Group (Nabholtz et al, 2003) | Open: 1996–1998 | AT (docetaxel+doxorubicin) | AC (cyclophosphamide+ doxorubicin) | Y | Y | 429 |
| Bontenbal (Bontenbal et al, 2003) | Open: 1997–2002. Abstract only | AT (docetaxel+doxorubicin) | FAC (fluorouracil+doxorubicin+ cyclophosphamide) | Y | Y | 216 |
| Nabholtz (Nabholtz et al, 2001) | Open: 1998–1999. Abstract only | TAC (docetaxel+doxorubicin+ cyclophosphamide) | FAC (fluorouracil+doxorubicin+ cyclophosphamide) | Y | N | 484 |
| EORTC 10961 (Biganzoli et al, 2002) | Open: 1996–1999 | AT (paclitaxel+doxorubicin) | AC (cyclophosphamide+ doxorubicin) | Y | Y | 275 |
| Jassem (Jassem et al, 2001) | Open: 1996–1998 | AT (paclitaxel+doxorubicin) | FAC (fluorouracil+doxorubicin+ cyclophosphamide) | Y | Y | 267 |
| AGO (Luck et al, 2000) | Open: 1996–1999. Abstract only | ET (paclitaxel+epirubicin) | EC (cyclophosphamide+epirubicin) | Y | Y | 505 |
| Bonneterre (Bonneterre et al, 2001) | Open: 1998–2000. Abstract only | ET (docetaxel+epirubicin) | FEC (fluorouracil+epirubicin+ cyclophosphamide) | Y | Both | 141 |
| UKCCCR AB01 (Carmichael, 2001) | Open: 1996–1999. Abstract only. | ET (paclitaxel+epirubicin) | EC (cyclophosphamide+epirubicin) | Y | Y | 705 |
| CECOG BM1 (Zielinski et al, 2001) | Open: 1999– (ongoing) | GET (paclitaxel, epirubicin, gemcitabine) | FEC (fluorouracil, epirubicin, cyclophosphamide) | Y | ? | Sample size unknown |
| Single agent taxane vs Regimen C | ||||||
| 303 Study Group (Chan et al, 1999) | Open: 1994–1997 | Docetaxel | Doxorubicin | N | Y | 326 |
| 304 Study Group (Nabholtz et al, 1999) | Open: 1994–1997 | Docetaxel | Mitomycin+vinblastine | N | N | 392 |
| Sjostrom (Sjostrom et al, 1999) | Open: 1994–1997 | Docetaxel | MF (methotrexate+fluorouracil) | N | N | 283 |
| TXT Group (Bonneterre et al, 2002) | Open: 1995–1997 | Docetaxel | FUN (fluorouracil+vinorelbine) | N | N | 176 |
| ANZ TITG (Bishop et al, 1999) | Open: 1993–1995 | Paclitaxel | CMFP (cyclophosphamide+ methotrexate+fluorouracil+ prednisone) | Y | Y | 209 |
| Dieras (Dieras et al, 1999) | Open: unk | Paclitaxel | Mitomycin | N | N | 81 |
| ECOG E1193 (B) (Sledge et al, 2003) | Open:1993–199 | Paclitaxel | Doxorubicin | Y | Y | 739 |
| EORTC 10923 (Paridaens et al, 2000) | Open: 1993–1996 | Paclitaxel | Doxorubicin | Y | Y | 331 |
| Talbot (Talbot et al, 2002) | Open: 1996–1997 | Paclitaxel | Capecitabine | N | N | 42 |
| TOG (Icli et al, 2002) | Open: 1997–2002. Abstract only | Paclitaxel | Cisplatin+VP-16 | N | N | 201 |
MBC=metastatic breast cancer.
a
All taxane-containing regimens were 3-weekly cycles.